Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 101 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CPI Clear all
Recruiting Phase 4 Interventional

Optimizing Perioperative Analgesia to Lower Pain Following Cleft Palate Surgery

NCT06962306
View directory record Official record
Conditions
Cleft Palate, Pain, Postoperative Care, Perioperative Care, Children
Interventions
Methadone hydrochloride, Fentanyl/Hydromorphone
Drug
Lead sponsor
Duke University
Other
Eligibility
6 Months to 4 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Completed No phase listed Observational

Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma

NCT06557291
View directory record Official record
Conditions
BRAF V600 Mutated-Stage III/IV Melanoma
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 20, 2026, 11:02 PM EDT
Active, not recruiting Phase 4 Interventional

Evaluation of Trigeminal Nerve Blockade

NCT03632044
View directory record Official record
Conditions
Mouth Abnormalities, Cleft Palate, Birth Defect
Interventions
Ropivacaine, Sham Comparator
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
3 Months to 5 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Not applicable Interventional

Smoking Cessation for HIV/AIDS Patients

NCT00502827
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Cell Phone Intervention, Recommended Standard of Care
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

Preoperative Alignment of Total Knee Replacement

NCT01242085
View directory record Official record
Conditions
Knee Arthritis
Interventions
trumatch group, control group
Procedure
Lead sponsor
VA Palo Alto Health Care System
Federal
Eligibility
18 Years to 90 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 20, 2026, 11:02 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

NCT05361174
View directory record Official record
Conditions
Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
IOV-4001
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Terminated Not applicable Interventional Results available

Exercises for Improving Soft Palate and Eustachian Tube Function in Children With Ear Tubes With or Without Cleft Palate

NCT03868891
View directory record Official record
Conditions
Cleft Palate, Tube Disorders Eustachian, Velopharyngeal Incompetence Due to Cleft Palate, Velopharyngeal Insufficiency
Interventions
EMST150
Device
Lead sponsor
Noel Jabbour
Other
Eligibility
6 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 20, 2026, 11:02 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

NCT05533697
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
mRNA-4359, Pembrolizumab, Ipilimumab, Nivolumab
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

NCT00054717
View directory record Official record
Conditions
HIV Infections
Interventions
Tipranavir, Ritonavir(r), Comparator Protease Inhibitor (CPI)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
96
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Not applicable Interventional Results available

Comparison of Surgical Time and Efficiency of Total Knee Arthroplasty

NCT01301950
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Custom Patient Instrumentation, Conventional Instruments
Other
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Mooresville, Indiana • Bartlesville, Oklahoma • Reston, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults

NCT05281263
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
CPI-RSV-F Vaccine (BLB-201)
Biological
Lead sponsor
Blue Lake Biotechnology Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Cincinnati, Ohio • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Not applicable Interventional

Improving Outcomes in Cleft Palate Surgery

NCT02583100
View directory record Official record
Conditions
Cleft Palate
Interventions
Intensive Feedback, Routine Feedback
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Phoenix, Arizona • Durham, North Carolina • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 20, 2026, 11:02 PM EDT
Completed No phase listed Observational

Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells

NCT03644498
View directory record Official record
Conditions
Cancer
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy

NCT00002209
View directory record Official record
Conditions
AIDS Dementia Complex, HIV Infections
Interventions
CPI-1189
Drug
Lead sponsor
Centaur Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 11:02 PM EDT
Completed No phase listed Observational

Study of Smith-Lemli-Opitz Syndrome

NCT00001721
View directory record Official record
Conditions
Smith-Lemli-Opitz Syndrome
Interventions
Cholesterol Suspension, CRH, Cholesterol
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 1 Interventional

ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer

NCT01963052
View directory record Official record
Conditions
Metastatic Urothelial Cancer
Interventions
AGS15E
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
Birmingham, Alabama • New Haven, Connecticut • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 20, 2026, 11:02 PM EDT
Recruiting No phase listed Observational

EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)

NCT03369821
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Beta Cell Loss and Immune Function, Immune Function with RNAseq
Diagnostic Test · Other
Lead sponsor
University of Exeter
Other
Eligibility
Up to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 20, 2026, 11:02 PM EDT
Withdrawn Phase 2 Interventional

GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

NCT06046274
View directory record Official record
Conditions
Advanced Endometrial Cancer
Interventions
Pembrolizumab, Acasunlimab
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Orlando, Florida • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 20, 2026, 11:02 PM EDT
Terminated No phase listed Observational

Survey Study and Records Review of Treatment Outcomes in Freeman-Sheldon Syndrome

NCT01144741
View directory record Official record
Conditions
Freeman-Sheldon Syndrome, Arthrogryposis Distal Type 2A, Whistling Face Syndrome, Craniocarpotarsal Dysplasia, Craniocarpotarsal Dystrophy, Freeman-Sheldon Syndrome Variant, Sheldon-Hall Syndrome, Arthrogryposis Distal Type 2B, Gordon Syndrome, Arthrogryposis Distal Type 3, Arthrogryposis Distal Type 1, Arthrogryposis, Distal, Type 1A, Arthrogryposis Distal Type 1B, Arthrogryposis, Distal, Craniofacial Abnormalities, Arthrogryposis
Interventions
PTSD Checklist-Civilian (PCL-C), Modified Flanagan Quality of Life Scale, Center for Epidemiologic Studies Depression Scale (CES-D), Functional Enquiry (or Review of Systems) Form, Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire, FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI), Medical Records Review
Other
Lead sponsor
Freeman-Sheldon Research Group, Inc.
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Buckhannon, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 20, 2026, 11:02 PM EDT
Terminated Phase 1 Interventional

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

NCT04261439
View directory record Official record
Conditions
In Escalation: All Patients With Solid Tumors and Lymphoma, In Expansion: Melanoma, Non-small Cell Lung Cancer
Interventions
NIZ985, Spartalizumab, Tislelizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Duarte, California • La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 20, 2026, 11:02 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

NCT03547973
View directory record Official record
Conditions
Metastatic Urothelial Cancer
Interventions
Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin, Avelumab, Zimberelimab, Carboplatin, Gemcitabine, Domvanalimab, Enfortumab Vedotin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
30
States / cities
Tucson, Arizona • San Francisco, California • Littleton, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

NCT04381650
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
TAK-981, Pembrolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
18
States / cities
Scottsdale, Arizona • Orange, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 20, 2026, 11:02 PM EDT
Recruiting Phase 2 Interventional

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

NCT04614103
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
LN-145
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
27
States / cities
Gilbert, Arizona • Miami, Florida • Tampa, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 20, 2026, 11:02 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

NCT04198766
View directory record Official record
Conditions
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
Interventions
INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2)
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2033
U.S. locations
30
States / cities
Duarte, California • Glendale, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 20, 2026, 11:02 PM EDT